Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Surprise! Saturn's huge moon Titan may not have a buried ocean after all - 2Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- 3It's time for Artemis II to break Apollo 13's distance record. What to know about the moon flyby
- 4Novo and Lilly cut prices of weight-loss drugs in China
- 5More loons are filling Maine's lakes with their ghostlike calls
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- 3D Printers for Specialists
- Enormous Credit And All that You Really want To Be aware
- My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Palestinian leader Abbas says elections only after Gaza war ends
- 7 Moves toward a Sound and Dynamic Way of life
- Everyday Seasonal Positions That Compensate Fairly in the US
- She just became the first wheelchair user to travel to space
